Denosumab: The first inhibitor of RANK-Ligand for treatment of osteoporosis;Denosumab: Erster RANK-ligand-inhibitor zur therapie der osteoporose

Medizinische Monatsschrift fur Pharmazeuten

Volumn 33, Issue 10, 2010, Pages 370-375

  Bruhn, Claudia ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

ARTICLE; BONE DENSITY; CELL ACTIVATION; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 78349257774     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Cummings SR, San Martin J, McClung M, Siris ES, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
2. Brown JP, Prince RL, Deal C, Recker RR, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase III trial. J Bone Miner Res 2009;24:153-61.
3. Bone HG, Bolognese MA, Yuen CK, Kendler DL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrin Metab 2008;93:2149-57.
4. Kendler DL, Roux C, Benhamou CL, Brown JP, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72-81.
5. Ellis GK, Bone HG, Chlebowski R, Paul D, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 2008;26:4875-82.
6. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.
7. Denosumab zeigt Überlegenheit gegenüber Zometa® hinsichtlich der Verzögerung von Komplikationen aufgrund von Knochenmetastasen bei Patienten mit fortgeschrittenem Prostatakrebs. Pressemeldung der Firma Amgen vom 18. Juni 2010.
8. Fizazi K, Carducci MA, Smith MR, Damião R, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA-4507). 2010 ASCO Annual Meeting, Vortrag am 6. Juni 2010.
9. Stopeck A, Body JJ, Fujiwara Y, Lipton A, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastasis: results of a randomized phase III study. Vortrag auf dem ESMO 2009, Berlin.
10. Henry D, von Moos R, Vadhan-Raj S, Hungria V, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastasis in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Can Suppl 2009;7:11, abstract 20LBA, Vortrag auf dem ESMO 2009, Berlin.
11. WHO Scientific Group on the prevention and management of osteoporosis (2000: Geneva, Switzerland). Prevention and management of osteoporosis: report of a WHO scientific group (WHO technical report series; 921). (http://whqlibdoc.who.int/trs/WHO-RS-21.pdf, Zugriff am 22.09.2010).
12. Lehmann G, Wolf G. Teriparatid - ein Überblick. Arzneimitteltherapie 2010;28:277-82.
13. Fachinformation Prolia®, Stand 05/2010.
14. Geusens P. Emerging treatments for postmenopausal osteoporosis - focus on denosumab. Clin Interven Aging 2009;4:241-50.
15. Hofbauer LC, Schoppet M. Clinical Implications of the Osteoprotegerin/RANKL/RANK System for bone and vascular diseases. JAMA 2004;292:490-5. (Pubitemid 38988958)